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To the Editor: 
 Limited long-term prospective data are available to characterize the impact of low rate 
smoking on lung health outcomes, particularly in population-based cohorts.  Prior studies have 
also differed in measurement of cumulative smoking exposure, with many studies relying on 
imprecise measurement and long periods of retrospective reporting. Smoking exposure is 
traditionally indexed by pack-years, and individuals with lifetime smoking thresholds below 10 
pack-years are typically excluded from clinical trials for chronic lung disease. However, recent 
studies have found smoking duration (i.e., years of cigarette smoking) to be superior to cigarettes 
per day or pack-years in predicting emphysema (1) and mortality (2). Low rate smoking is 
increasingly prevalent, with 25% of smokers in the U.S. currently consuming fewer than 10 
cigarettes per day, and a growing body of literature has identified negative health effects 
associated with low rate smoking, including cardiovascular disease, cancer, and all-cause 
mortality (2-4). Using data from the Coronary Artery Risk Development in Young Adults 
(CARDIA) study, we studied how longitudinal patterns of smoking exposure – based on 
cigarettes per day reported annually over 25 years of follow-up – are associated with loss of lung 
function, incident obstructive lung physiology, and CT-measured emphysema. 
Methods 
 CARDIA is a prospective cohort study of the evolution of cardiovascular disease risk 
factors in 5115 young adults initiated in 1985 (5).  Participants were invited to complete follow-
up exams at Years 2, 5, 7, 10, 15, 20, 25, and 30 with 91%, 86%, 81%, 79%, 74%, 72%, 72%, 
and 71% retention. Cigarette smoking was evaluated during each in-person CARDIA visit and at 
annual phone assessments. We used group-based zero-inflated Poisson (ZIP) trajectory modeling 
(SAS PROC TRAJ) to identify distinct patterns of smoking among participants, by including all 
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ever smokers who had data recorded on number of cigarettes smoked per day for at least 3 of the 
26 annual queries taken from Year 0 to Year 25 (6). Trajectories of cigarettes/day were specified 
as a function of participant age using third-order polynomials for both the cigarettes/day Poisson 
count model and the logit model for predicting extra zeros. 
Incident obstructive lung physiology was defined as having a post-bronchodilator forced 
expiratory volume in 1 second (FEV1) / forced vital capacity (FVC) ratio < 70% at the Year 30 
examination but not at the time of peak lung function. Emphysema at Year 25 was determined by 
visual review of CT scans (7). 
 We examined the associations of each lifetime smoking trajectory group with lung 
function decline and risk of future lung disease, relative to never-smokers. Logistic regression 
models examined smoking trajectory group as a predictor of emphysema on the Year 25 CT scan 
and Year 30 obstructive lung physiology, adjusting for age, race-sex group, center, height, BMI, 
physician-confirmed asthma, baseline cigarettes per day, and baseline pack-years. 
Results 
 Life-course smoking trajectories are presented in Figure 1.  Although the Bayesian 
Information Criterion (BIC) indicated a slightly better fit of the seven- versus six-group model, 
visual inspection of the trajectory group plots suggested greater parsimony in the six-group 
model presented below. Trajectory group membership was associated with lung function decline 
in a stepwise manner by smoking exposure, with heavy stable smokers showing the greatest 
decline in FEV1 (-42.2 mL/year; Table 1). Smoking trajectory groups differed in risk of incident 
obstructive lung physiology, with heavy stable smokers vs. never-smokers demonstrating nearly 
eight times the odds of obstructive disease and more than twenty times the odds of CT 
emphysema (Table 1).  Among the two low rate smoking groups (low rate stable smokers and 
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quitters), quitters showed less FEV1 decline (-33.8 mL/year vs. -35.7 mL/year) and lower 
emphysema odds than low rate stable smokers despite having greater mean lifetime pack-years 
(9.8 vs. 6.4, using 20 cigarettes per pack). 
Discussion 
 In a longitudinal, community-based study, we identified a dose-response relationship of 
smoking exposure with lung function decline and lung disease risk. Trajectory analyses indicated 
distinct patterns of life-course smoking, which were differentially associated with lung disease 
risk. Among the two low rate groups, quitters preserved more lung function and reduced their 
lung disease risk, relative to low rate stable smokers. These results highlight that there is no safe 
threshold of sustained smoking with regard to lung disease risk. 
 The current manuscript extends prior findings on the utility of smoking duration as a 
predictor of lung health outcomes. Measurement of smoking using pack-years is imprecise (8) 
and raises concerns of inaccurate reporting and recall bias, especially for individuals whose 
smoking rate is low or fluctuating. Years smoking may be a more sensitive, reliable, and efficient 
operational index of smoking exposure in predicting lung disease risk.   
 Our findings add to a growing body of research on associations between smoking 
duration and disease risk (2). We identified marked increases in lung disease risk among ever 
versus never smokers – even among low rate stable smokers, for whom there was nearly three 
times the risk of incident obstruction and more than an eight-fold increase in CT emphysema 
risk. As missing data was more common among participants with greater smoking exposure, our 
analyses are biased toward the null, and effect sizes likely underestimate the true disease risk 
among heavy smokers. Further, while our approach adjusted for participant-level peak lung 
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function, we were unable to examine the main effect of peak lung function on subsequent disease 
risk.(9, 10)  
 Given that an increasing proportion of individuals smoke at a low or intermittent rate (3), 
our findings have important public health implications. As compared to never-smokers, low rate 
smokers demonstrated increased disease risk, despite a relatively low threshold of lifetime 
smoking exposure (6.4 pack-years). Targeted messaging is needed to reiterate the lung health 
risk of sustained smoking at any level. Additionally, healthcare providers should underscore the 
lung health benefit of smoking cessation over and above smoking reduction (i.e., cutting down 
on cigarettes per day without intention to quit). Although smoking reduction may be a positive 
initial step toward cessation, prospective studies demonstrate limited lung health benefits of 
smoking reduction alone (11). This is likely due to changes in smoking topography, in which 
smokers inhale more deeply and/or smoke more puffs of each cigarette to compensate for a 
lower number of cigarettes per day. Our findings are consistent with the message that quitting, 
and not cutting down, is the most effective method of reducing lung disease risk.  
 Smoking influenced lung disease risk in a dose-dependent manner.  There was no safe 
threshold for smoking intensity on lung disease risk and even low-rate smokers were at increased 
risk for future lung disease. These results underscore the benefit of complete abstinence from 
smoking even among low rate smokers on respiratory outcomes. 
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Table 1. Smoking trajectory group, mean FEV1 decline, and association (covariate adjusted odds ratio) with incident lung 
disease  
 
Smoking 
Trajectory 
Group 
FEV1 decline, 
mL/year (SEM) 
Incident Lung Disease 
Pre-
bronchodilator 
Obstructive, 
OR (95% CI) 
Post-
bronchodilator 
Obstructive, 
OR (95% CI) 
Centrilobular 
Emphysema, 
OR (95% CI)
 
Paraseptal 
Emphysema, 
OR (95% CI) 
Any Emphysema 
(Paraseptal or 
Centrilobular), 
OR (95% CI) 
Never smokers -32·48 (0·35) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 1·0 (ref) 
Minimal 
smokers 
-32·34 (0·53) 1·36 
(0·98, 1·88) 
1·42 
(0·86, 2·35) 
1·81 
(0·64, 5·15) 
1·59 
(0·62, 4·09) 
1·44 
(0·66, 3·13) 
Low rate stable 
smokers 
-35·70 (0·83) 2·44 
(1·59, 3·72) 
2·80 
(1·55, 5·06) 
9·60 
(4·04, 22·84) 
11·24 
(5·42, 23·31) 
8·45 
(4·52, 15·82) 
Quitters -33·80 (0·93) 1·19 
(0·69, 2·03) 
2·03 
(1·02 4·06) 
5·85 
(2·13, 16·04) 
3·79  
(1·46, 9·87) 
3·44 
(1·53, 7·71) 
Moderate stable 
smokers 
-38·46 (0·87) 3·15 
(2·06, 4·81) 
5·34 
(3·10, 9·19) 
25·72 
(11·63, 56·88) 
21·27 
(10·59, 42·73) 
20·10 
(11·15, 36·22) 
Heavy stable 
smokers  
-42·19 (1·12) 4·20 
(2·52, 6·98) 
7·44 
(3·94, 14·06 ) 
37·56 
(15·87, 88·89) 
25·37 
(11·68, 55·18) 
26·01 
(13·36, 50·63) 
Heavy declining 
smokers 
-41·29 (1·97) 3·04 
(1·36, 6·76) 
7·54 
(2·92, 19·47) 
35·53 
(11·33, 111·38) 
26·98 
(9·25, 78·70) 
25·40 
(9·82, 65·67) 
 
Note. FEV1 decline values reflect mean (SE) adjusted annualized decline in lung function from peak measurement to Year 30. Incident 
lung disease values reflect odds ratios (OR) and 95% confidence intervals (in parentheses). Never smokers were the reference group 
for all models. Obstructive lung disease indicates FEV1/FVC value < 70% at the Year 30 examination but not at the time of peak lung 
function. 
 
Covariates: baseline age, race-sex group, center, height, baseline BMI, physician-confirmed asthma, baseline cigarettes per day, and 
baseline pack-years. 
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Figure Legend 
 
Figure 1.  Lifetime smoking trajectories by cigarettes per day reported annually over 25 
years.  Group-based trajectory modeling was used to generate trajectories of lifetime cigarette 
smoking. Group compositions were as follows: Heavy declining smokers (4·7%, n=125, mean 
lifetime cumulative pack-years 38·2), Heavy stable smokers (15·3%, n=406, mean lifetime 
cumulative pack-years 28·2), Moderate stable smokers (18·4%, n=488, mean cumulative pack-
years 15·5), Quitters (12·4%, n=327, mean cumulative pack-years 9·8), Low rate stable smokers 
(15·9%, n=420, mean cumulative pack-years 6·4), Minimal smokers (33·3%, n=881, mean 
cumulative pack years 2·1).  
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